GS-248

GS-248 · Gesynta Pharma AB

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for GS-248, covering 2021-08-31 to 2024-08-09. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis [Phase 2]